Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thiazolidinediones and hepatic fibrosis: don't wait too long.

Literature DB >> 16766749

Thiazolidinediones and hepatic fibrosis: don't wait too long.

F Marra¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2006 PMID： 16766749 PMCID： PMC1856323 DOI： 10.1136/gut.2005.085399

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

24 in total

Review 1. Thiazolidinediones.

Authors: Hannele Yki-Järvinen
Journal: N Engl J Med Date: 2004-09-09 Impact factor: 91.245

Review 2. Steatosis: co-factor in other liver diseases.

Authors: Elizabeth E Powell; Julie R Jonsson; Andrew D Clouston
Journal: Hepatology Date: 2005-07 Impact factor: 17.425

3. Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice.

Authors: Yutaka Inagaki; Miwa Kushida; Kiyoshi Higashi; Johbu Itoh; Reiichi Higashiyama; Yun Yu Hong; Norifumi Kawada; Kazuhiko Namikawa; Hiroshi Kiyama; George Bou-Gharios; Tetsu Watanabe; Isao Okazaki; Kazuo Ikeda
Journal: Gastroenterology Date: 2005-07 Impact factor: 22.682

4. Adipogenic transcriptional regulation of hepatic stellate cells.

Authors: Hongyun She; Shigang Xiong; Saswati Hazra; Hidekazu Tsukamoto
Journal: J Biol Chem Date: 2004-11-09 Impact factor: 5.157

5. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

Authors: Anna Planagumà; Joan Clària; Rosa Miquel; Marta López-Parra; Esther Titos; Jaime L Masferrer; Vicente Arroyo; Joan Rodés
Journal: FASEB J Date: 2005-05-04 Impact factor: 5.191

Review 6. Liver fibrosis.

Authors: Ramón Bataller; David A Brenner
Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808

7. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Authors: Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon
Journal: Hepatology Date: 2003-10 Impact factor: 17.425

8. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

Authors: Kittichai Promrat; Glen Lutchman; Gabriel I Uwaifo; Renee J Freedman; Alejandro Soza; Theo Heller; Edward Doo; Marc Ghany; Ahalya Premkumar; Yoon Park; T Jake Liang; Jack A Yanovski; David E Kleiner; Jay H Hoofnagle
Journal: Hepatology Date: 2004-01 Impact factor: 17.425

9. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.

Authors: Kotaro Kawaguchi; Isao Sakaida; Masako Tsuchiya; Kaoru Omori; Taro Takami; Kiwamu Okita
Journal: Biochem Biophys Res Commun Date: 2004-02-27 Impact factor: 3.575

10. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells.

Authors: Saswati Hazra; Shigang Xiong; Jiaohong Wang; Richard A Rippe; V Krishna; K Chatterjee; Hidekazu Tsukamoto
Journal: J Biol Chem Date: 2003-12-31 Impact factor: 5.157

3 in total